{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:41:43Z","timestamp":1777434103506,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Australas Psychiatry"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We present an evaluation of antipsychotic prescribing in an inpatient psychiatry ward in Hobart, Tasmania, to establish pattern of use, alignment with other psychiatric wards or\u00a0centres and the recommendations in the Royal Australian and New Zealand College of Psychiatry Clinical Practice Guidelines, and to determine predictors of polypharmacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A descriptive cross-sectional survey design was used. Data from 118 patients discharged from the Royal Hobart Hospital (RHH) Mental Health Inpatient Unit between 01\/02\/2021 to 01\/08\/2021 were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Antipsychotic polypharmacy (APP) was observed in 40% of patients. When low doses of adjunctive (\u2018PRN\u2019) use of olanzapine and quetiapine were excluded, the APP proportion was 35%. APP was predicted by age and by a schizophrenia diagnosis. Long-acting injections (LAIs) were used in 46% of the patients. The most common LAI was risperidone (52%). Average daily dose of antipsychotic at the time of discharge was 529\u00a0mg chlorpromazine (CPZ) equivalents. High dose antipsychotics (more than 1000\u00a0mg CPZ equivalents per day) was observed in 13% of the patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The observed prescribing practice is consistent with other clinical settings. Antipsychotic prescribing practice should, however, continue to be monitored to ensure adherence to best practice guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10398562241283156","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T01:59:58Z","timestamp":1726279198000},"page":"134-139","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterising the nature of psychiatric disorders and patterns of antipsychotic medications prescribed in a psychiatric ward in a public hospital in Tasmania"],"prefix":"10.1177","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1656-4766","authenticated-orcid":false,"given":"Sharad","family":"Tamrakar","sequence":"first","affiliation":[{"name":"Royal Hobart Hospital, Tasmanian Health Service, Glenorchy, TAS, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Mendoza Diaz","sequence":"additional","affiliation":[{"name":"Tasmanian Centre for Mental Health Service Innovation, Tasmanian Health Service, Hobart, TAS, Australia; and Discipline of Psychiatry &amp; Mental Health, School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2217-1401","authenticated-orcid":false,"given":"Adriana G","family":"Nevarez Flores","sequence":"additional","affiliation":[{"name":"Tasmanian Centre for Mental Health Service Innovation, Tasmanian Health Service, Hobart, TAS, Australia; and Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Castle","sequence":"additional","affiliation":[{"name":"Tasmanian Centre for Mental Health Service Innovation, Tasmanian Health Service, Hobart, TAS, Australia; and School of Medicine, University of Tasmania, Hobart, TAS, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"e_1_3_6_2_2","first-page":"000486742312098","article-title":"Seven decades of antipsychotic drugs: why is the life of Australians with schizophrenia still so suboptimal?","volume":"21","author":"Castle D","year":"2023","unstructured":"Castle D, Copolov D, Singh B, et al. Seven decades of antipsychotic drugs: why is the life of Australians with schizophrenia still so suboptimal? Aust N Z J Psychiatr 2023; 21: 00048674231209840.","journal-title":"Aust N Z J Psychiatr"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/00048674231210209"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-006-9063-1"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1192\/pb.bp.107.016899"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145712000399"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13072073"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.09060802"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.6.553"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.7.921"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/1039856215626644"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8403986"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230180"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20387"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.4320"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/10398562221142453"},{"key":"e_1_3_6_17_2","first-page":"6","volume-title":"The risks and benefits of high dose antipsychotic medication. Report CR 190","author":"Royal College of","year":"2014","unstructured":"Royal College of (2014) Psychiatrists. The risks and benefits of high dose antipsychotic medication. Report CR 190. London: Royal College of Psychiatrists, 6."},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp130"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.03.013"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1173"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1192\/pb.24.4.130"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/0004867413488221"},{"issue":"2","key":"e_1_3_6_23_2","first-page":"1","article-title":"Graylands hospital drug bulletin: antipsychotic polypharmacy\u2013time to review practice","volume":"20","author":"Luft B","year":"2013","unstructured":"Luft B (2013) Graylands hospital drug bulletin: antipsychotic polypharmacy\u2013time to review practice. North Metropolitan Health Service\u2013Mental Health 20(2): 1\u20134.","journal-title":"North Metropolitan Health Service\u2013Mental Health"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.10.015"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2083"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0004867412450471"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04912gre"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13369"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/1039856214546672"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz068"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/0004867416641195"}],"container-title":["Australasian Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10398562241283156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10398562241283156","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10398562241283156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:52:48Z","timestamp":1777377168000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10398562241283156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/10398562241283156"],"URL":"https:\/\/doi.org\/10.1177\/10398562241283156","relation":{},"ISSN":["1039-8562","1440-1665"],"issn-type":[{"value":"1039-8562","type":"print"},{"value":"1440-1665","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]}}}